Bayer Taps New CEO

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 18 No 10
Volume 18
Issue 10

Bayer has announced that Marijn Dekkers, PhD, will succeed Werner Wenning as CEO starting October 1, 2010.

Bayer has announced that Marijn Dekkers, PhD, will succeed Werner Wenning as CEO starting October 1, 2010. Dr. Dekkers will join the company's board at the start of 2010 and will also serve as CEO of Bayer's healthcare division. He is currently president and CEO of Thermo Fisher Scientific.

Articles in this issue
Cancer, not HPV vaccination, hastened death of UK girl
Obesity hinders treatment in pediatric leukemia
Posaconazole reduces infection in AML patients
Global report warns of escalating cancer rate
Antidepressants continue to show increased inhibition of colorectal tumor cell growth
New class of alpha emitters takes aim at bone metastases
Who's News
Stop and smell the volatile organic compounds in lung ca
Proton therapy report advises caution
From anthracyclines to anti-VEGF: Shifts in the adjuvant treatment of breast cancer
Will Chemoradiotherapy End Surgical Dominance in the Treatment of Squamous Cell Head and Neck Cancers
Circulating tumor cells edge out imaging in breast mets
Smoking cessation requires unremitting reinforcement
Industry Watch
Avastin Breast Rx Trial Enrollment Halted Due to Cardiotoxicity Cases
Recent Videos
Retrospective and real-world registry studies may be necessary to guide clinical decision-making for rarer lymphomas with insufficient prospective data.
Addressing Limitations to Clinical Trial Development for Lymphoma Treatment
Extravasation results in exposing healthy tissue to radiation, which can be highly dosed depending on the isotope used for treatment.
Bill Seeks to Require Reporting of Extravasated Tissue in Radiology
Epithelioid Sarcoma: Histological Features and Differential Diagnoses
Epithelioid Sarcoma: Histological Features and Differential Diagnoses
Epithelioid Sarcoma: Overview and Presentation
Epithelioid Sarcoma: Overview and Presentation
4 experts in this video
Leveraging PSMA PET Imaging in Posttreatment Response Assessment: Evolving Practices and Data Insights
2 experts in this video
Decision-Making Factors in Choosing Combination Therapies in EGFR-Mutated NSCLC
2 experts in this video
Evaluating Chemotherapy-Free vs Chemotherapy-Containing Combos in First-Line EGFR-Mutated NSCLC: Pros and Cons
4 experts in this video
Role of PSMA PET Imaging in Guiding Surgical Treatment Decisions in Prostate Cancer
Ongoing studies seek to evaluate immunotherapy in earlier lines of therapy for patients with early-stage Hodgkin lymphoma.
Outlining Ongoing Clinical Developments in Treatment for Rare Lymphomas
Strict inclusion criteria may disproportionately exclude racial minority populations from participating in breast cancer trials.
Addressing Racial Disparities, Social Barriers to Breast Cancer Care
Related Content
Phase 3 data support using twice-daily high-dose thoracic radiotherapy plus concurrent chemotherapy as an alternative therapy for patients with LS-SCLC.

High-Dose Radiotherapy Boosts Survival Without Toxicity Increase in LS-SCLC

Russ Conroy
April 20th 2025
Article

Phase 3 data support using twice-daily high-dose thoracic radiotherapy plus concurrent chemotherapy as an alternative therapy for patients with LS-SCLC.

Fostering the Future of Psychosocial Care With World Psycho-Oncology Day

Fostering the Future of Psychosocial Care With World Psycho-Oncology Day

Cristiane Decat Bergerot, PhD
April 14th 2025
Podcast

Integrating psychosocial care into cancer care allows patients to receive emotional support, counseling, and coping strategies to help navigate treatment.

End-of-life demands card game and mindfulness-based cancer recovery program use may enhance the quality of life for patients with lung cancer.

Mindfulness/Activity Program May Ease Anxiety Over Death from Lung Cancer

Roman Fabbricatore
April 19th 2025
Article

End-of-life demands card game and mindfulness-based cancer recovery program use may enhance the quality of life for patients with lung cancer.

Experts from Sibley Memorial Hospital discuss how multidisciplinary work has enhanced outcomes such as survival and resource use at their institution.

Elevating the Quality of Cancer Care via Cross-Department Collaboration

Rachit Kumar, MD;Michael J. Pishvaian, MD, PhD;Nina D. Wagner-Johnston, MD;Valerie Lee, MD;Armine K. Smith, MD;Pouneh Razavi, MD;Curtiland Deville Jr., MD
April 7th 2025
Podcast

Experts from Sibley Memorial Hospital discuss how multidisciplinary work has enhanced outcomes such as survival and resource use at their institution.

96 Elacestrant Real-World Progression-Free Survival of Adult Patients With ER+/HER2–, Advanced Breast Cancer: A Retrospective Analysis Using Insurance Claims in the United States

96 Elacestrant Real-World Progression-Free Survival of Adult Patients With ER+/HER2–, Advanced Breast Cancer: A Retrospective Analysis Using Insurance Claims in the United States

Elyse Swallow;Jessica Maitland;Kirthana Sarathy;Ellen Sears;Yasir Nagarwala;Janelle DePalantino;Eric Kruep;Corey Pelletier;Sebastian Kloss;Tomer Wasserman
April 18th 2025
Article
Patients with painful lesions who did not undergo treatment with opioids or reirradiation generally had better outcomes than those who did.

Classification System May Identify QOL Benefit with Palliative Radiotherapy

Roman Fabbricatore
April 18th 2025
Article

Patients with painful lesions who did not undergo treatment with opioids or reirradiation generally had better outcomes than those who did.